Sapanisertib
- Generic Name
- Sapanisertib
- Drug Type
- Small Molecule
- Chemical Formula
- C15H15N7O
- CAS Number
- 1224844-38-5
- Unique Ingredient Identifier
- JGH0DF1U03
- Background
Sapanisertib has been used in trials studying the treatment of HCC, Solid Tumor, Gliosarcoma, Liver Cancer, and Glioblastoma, among others.
Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors
- Conditions
- Recurrent Malignant Solid NeoplasmRefractory Malignant Solid Neoplasm
- Interventions
- First Posted Date
- 2018-02-13
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 35
- Registration Number
- NCT03430882
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of TAK-228 as Single Agent in Adult East Asian Participants With Advanced Nonhematological Malignancies
- First Posted Date
- 2017-12-12
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Calithera Biosciences, Inc
- Target Recruit Count
- 28
- Registration Number
- NCT03370302
- Locations
- 🇨🇳
National Taiwan-University Hospital, Taipei, Taiwan
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
🇯🇵National Cancer Center Hospital, Chuo-ku, Tokyo-To, Japan
Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas
- Conditions
- Anaplastic Large Cell LymphomaClassical Hodgkin LymphomaMalignant Neoplasms Stated as Primary Lymphoid HaematopoieticCD30+ Peripheral T-cell Lymphoma
- Interventions
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2018-01-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT03205891
Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors
- Conditions
- Advanced Solid Tumor
- Interventions
- First Posted Date
- 2017-05-16
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Avera McKennan Hospital & University Health Center
- Target Recruit Count
- 19
- Registration Number
- NCT03154294
- Locations
- 🇺🇸
Avera Cancer Institute, Sioux Falls, South Dakota, United States
Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma
- First Posted Date
- 2017-03-31
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Bradley A. McGregor, MD
- Target Recruit Count
- 39
- Registration Number
- NCT03097328
- Locations
- 🇺🇸
University of California, San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations
- Conditions
- Locally Advanced Bladder Urothelial CarcinomaMetastatic Urothelial CarcinomaRecurrent Bladder CarcinomaStage III Bladder Urothelial Carcinoma AJCC v6 and v7Metastatic Transitional Cell CarcinomaStage IV Bladder Urothelial Carcinoma AJCC v7
- Interventions
- First Posted Date
- 2017-02-08
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 17
- Registration Number
- NCT03047213
- Locations
- 🇺🇸
Keck Medical Center of USC Pasadena, Pasadena, California, United States
🇺🇸Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, United States
🇺🇸Los Angeles General Medical Center, Los Angeles, California, United States
Sapanisertib and Metformin in Treating Patients With Advanced or Metastatic Relapsed or Refractory Cancers
- Conditions
- Advanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmRecurrent Malignant Solid NeoplasmRefractory Neoplasm
- Interventions
- First Posted Date
- 2017-01-11
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 31
- Registration Number
- NCT03017833
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer
- Conditions
- Estrogen Receptor Positive Breast Cancer
- Interventions
- First Posted Date
- 2016-12-12
- Last Posted Date
- 2021-09-22
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 28
- Registration Number
- NCT02988986
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
🇺🇸Houston Methodist Hospital Willowbrook, Houston, Texas, United States
🇺🇸Houston Methodist Hospital Sugar Land, Sugar Land, Texas, United States
Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas
- First Posted Date
- 2016-12-09
- Last Posted Date
- 2022-10-14
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT02987959
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery
- Conditions
- Pancreatic Neuroendocrine Tumor G1Pancreatic Neuroendocrine Tumor G2Refractory Pancreatic Neuroendocrine Carcinoma
- Interventions
- First Posted Date
- 2016-09-09
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 13
- Registration Number
- NCT02893930
- Locations
- 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸Bhadresh Nayak MD PC-Sterling Heights, Sterling Heights, Michigan, United States
🇺🇸Central Care Cancer Center - Bolivar, Bolivar, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.